Built from AlignedCardio proforma (SHRC). Adjust assumptions to compare real physician outcomes under each path. No login required — works fully offline.
Volume assumptions
Vendor deal assumptions
Vendor subsidy$2.2M
Supply premium over market20%
Premium applies only during commitment period, then drops to $0
Exit EBITDA multiple8x
Applied to Year 5 EBITDA for equity value
Execution risk — independent path only
AlignedCardio absorbs 100% of cost overruns and opening delays. The physician group carries these entirely on the independent path.
Execution risk75%
Dev cost overrun
75%
Opening delay
14 mos
Cost overrun (manual)75%
Delay months (manual)14 mos
View period
Independent — vendor financed
Cases
Revenue
Supply premium
Commitment payoff
Cost overrun (amort./yr)
Delay EBITDA loss (Yr 1)
Total capital at risk
Execution risk100% physician
AlignedCardio platformNone
AlignedCardio partnership — 30% to group
Cases
Revenue
Supply premium$0
Commitment payoffN/A
Cost overrun riskAC absorbs
Delay riskAC absorbs
Capital at risk$0
Execution riskShared with AC
AlignedCardio platformYes — referrals + ops
Annual cash comparison — $000s
Independent (after exec risk)AlignedCardio 30%
Independent path shows full facility EBITDA; AlignedCardio path shows physician net share (30%). Not a direct comparison.
Proforma anchors (SHRC model)
Total project cost: $4.0M · AC equity contribution: $388K · Equipment loan: $1.149M · Yr 1 EBITDA: $313K (9.6% margin) · Yr 5 EBITDA: $1.275M (21.4% margin) · Revenue CAGR: 16.2% · 5-yr physician cumulative net (base): $1.27M · 5-yr AC cumulative income: $4.93M